Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Stryker Corporation

SYK Healthcare Unknown Updated July 31, 2026
$325.56
52W $281.00 – $396.86
56/100
$124.86B
33.5
0.78
AI Committee Verdict
Watch
Conviction: Moderate · 67% agreement · 6 analysts
+14.9%
-3.2%
4.62:1
Moderate

Is SYK Bullish or Bearish?

Mixed. Innellis AI committee rates Stryker Corporation (SYK) Watch with a composite score of 56/100 , based on 6 analysts with 67% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +4.06 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -15.94 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Some positive signals exist — news sentiment is positive (+0.20 across 50 articles, 14d) — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • ROE of 15.1% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.20 across 50 articles, 14d) — News
Bear Case
  • P/E of 37.3 is moderate-to-rich — Value
  • Price-to-book of 6.0x prices in significant intangible value — Value
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
56/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 49%
of 93 Healthcare peers
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 15.1% shows genuine earnings power backing the valuation
− P/E of 37.3 is moderate-to-rich
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 50 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score strengthened from 52.1 to 55.9.

Analyst-level changes:
  • Growth Analyst: stance bearish->bullish; score 38->62 (+25); +1 bullish signal(s).
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • News Analyst: score 68->64 (-4); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Technical Analyst: score 48->58 (+10).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
45.3
Neutral
MACD Histogram
1.411
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$315.07
Resistance
$373.99
Bollinger %B
0.46
Inside Bands
Price vs Moving Averages
EMA 9
$334.11 Below
EMA 21
$327.97 Below
EMA 50
$322.73 Above
EMA 200
$338.48 Below

Fundamental Analysis

Valuation
53
Growth
24
Profitability
1
Financial Health
98
Cash Flow
37
Valuation
P/E Ratio 33.5×
P/B Ratio 5.21×
PEG Ratio 1.23
Dividend Yield 0.01%
52W High $396.86
52W Low $281.00
Quality & Growth
ROE 14.5%
ROA 6.8%
Gross Margin 65.2%
Operating Margin 22.0%
Revenue Growth YoY
Debt / Equity 0.59
AI Fundamental Assessment
P/E ratio of 33.5 (rich relative to a 15-40x range); Price-to-book of 5.2x; PEG ratio of 1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.1%; Gross margin of 0.7%; Current ratio of 2.16 (healthy short-term liquidity); Debt-to-equity of 0.59; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (12.26); Most recent quarter missed estimates by 13.7%; EPS growth decelerating (+0.0% -> -41.8% QoQ); Analyst estimates falling over recent quarters
Get the Full SYK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore SYK Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime